"18 months of departure spells" reappeared, Mu Yanping, general manager of Elis, resigned

Another innovative pharmaceutical company failed to retain executives from foreign companies.

On September 14, Elis issued an announcement saying that the company's general manager Mu Yanping applied for resignation for personal reasons, and since then he still served as a company consultant.

Mu Yanping worked in clinical doctors after graduating from Shanghai Medical College in 1989. In 1996, he was transferred to medical sales in "abandoned medical care" and served many well -known multinational pharmaceutical companies such as GlaxoSmithk, Aslekang, Johnson & Johnson, and Merck.

Before joining Elis, Mu Yanping served as the managing director of the Merida Tumor Division. From 2017 to 2020, he formed and managed the K drug sales team, and helped Merhado achieve a sales performance of $ 500 million in 2019.

In March 2020, Mu Yanping set foot on the largest investment "air outlet" in the pharmaceutical industry and chose to join Elis. As an innovative pharmaceutical company listed from the Science and Technology Board, Elis broke the losing "curse" in just one year and achieved a profit of turning losses. Mu Yanping contributed.

This time Mu Yanping chose to leave, making the outside world very strange.

Company executives leave, the commercialization of core varieties may change

Elis has advertised himself as an innovative pharmaceutical company, which has been established for more than 18 years.

In 2004, Guo Jianhui, a returning scientist, met with Du Jinhao, who had been in the construction industry for many years. Perhaps it was the reason why the two people in Jiangsu Qidong. As early as 2000, Guo Jianhui discovered the molecular structure of Alichardone and applied for a patent in the United States. Alice Tastein was listed as the first domestic 1.1 -category anti -hypertension Saltic drug in July 2012. Unfortunately, Guo Jianhui died of illness in the same year.

After losing the technical "General Commander", Du Jinhao sold Altarta to Xinlitai, and also found the Dr. Luo Huibing of the Pharmaceutical Chemistry of the Chinese Academy of Sciences. In the end, Elis developed a core product Fu Meidoni.

Mu Yanping resigned from Meridadon in March 2020 and joined Elis. One month later, Alex submitted a listing application to the Science and Chuangban, and was successfully listed at the end of the year. In March 2021, Fumin Nignine was approved for listing. The indication was the local advanced or metastatic non -small cell lung cancer of EGFR T790M mutant.

This is the third -generation EGFR product approved by the domestic paragraph. At that time, the industry believed that the listing of Fumidini was expected to replace Astrikon's Osteinib and Jiangsu Haosen's Aceitinib market share. Elis naturally hopes to quickly start the commercialization process and seize the position of major variety such as Astrikon's "Tyrusa".

Mu Yanping helped Elis build a sales team of about 480 people. The turnover of Fuminni 2021 exceeded 200 million yuan in the first year. After entering the medical insurance catalog at the end of 2021, in just 6 months, Famiminib's sales have reached 299 million yuan.

As of the end of June 2022, Elis has formed a marketing team covering 30 provinces and cities, covering 1,000 hospitals and 500 DTP pharmacies in the core market. In addition, commercial partners Jiangsu Fosun covers more than 1,500 hospitals in the vast market. In the prospectus, Elis is expected to occupy about 20%to 25%of the third -generation EGFR pharmaceutical market in 2023, so that the scale of terminal sales is expected to reach 1.83 billion yuan to 2.74 billion yuan.

Elis, which has both heavy products and commercial channels, has entered a benign track.

Mu Yanping suddenly resigned for "personal reasons".

There is a gap between local foreign capital, who can break the 18 -month -old resignation spell

Mu Yanping has not yet announced her next stop, but the industry generally believes that in today's medical environment, there are real materials and talents who can complete the company's set sales tasks. They do not worry about finding jobs.

On the other hand, Alex, after losing a sales general, how to stabilize the team to ensure the current sales momentum of sales is the top priority.

Du Jinhao relied on construction projects. It was considered a foreigner for medicine. At the beginning of the in charge of Elis, he did not use all the money on the development of new drugs. The prospectus shows that before 2017, Elis lent the funds obtained by the transfer of Alicharine to others. Du Jinhao is mainly borrowed by Du Jinhao's friends and partners engaged in the construction of the construction and real estate development industry.

By the end of 2017, Alex borrowed a total of 246 million yuan, and the interest receivable was 10.9 million yuan, totaling 257 million yuan. These borrowings basically hollowed out Elis. At that time, the company's book funds were only 59 million yuan. The misappropriation of funds that should be used for new drugs is obviously a manifestation of "do not do business".

After Mu Yanping's employment, Alex's development gradually moved to the right track, but she admitted to the media that domestic pharmaceutical companies and foreign pharmaceutical companies still have a large difference.

Mu Yanping believes that multinational pharmaceutical companies not only have a mature globalization model, but also have a comprehensive talent system. China's innovative drug companies are still in their infancy, and the process system and operating mechanism need to be improved and optimized.

In fact, the talents of multinational pharmaceutical companies have joined the local pharmaceutical companies, which is undoubtedly affirming China's medical innovation capabilities and development space. However, the local innovative pharmaceutical companies are not easy to retain after introducing talents.

There are even more than 18 months of transnational pharmaceutical company executives who will resign.

In April of this year, Murishadon announced that Luo Wanli, who had joined the Xingxing Pharmaceutical, would return in August; in February, Qian Wei, who served as CCO for 5 months, decided to return to the old owner Luo Shi; after Chu Nan left RocheI went to Junshi Bio as the vice president of marketing and medical affairs. As a result, I also joined Pfizer at the end of March this year.Multinational pharmaceutical companies have grown for many years, and the investment philosophy and business direction of the capital behind them are relatively mature. These pharmaceutical companies have supported all aspects of the Chinese market; most of the local pharmaceutical companies are flat management, and the functional division of the department may not be clear.There are no middle levels that can be commanded, and one person must be a number of positions.

China is transforming from a large pharmaceutical country to a powerful country, and the two -way circulation of talents is normal.Analysts pointed out that the heads of domestic pharmaceutical companies must master the laws of medical development, not to work hard, and do the right thing according to industry trends.

Writing ｜ Xiaomi

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

Illustration ｜ Visual China

### 力#

- END -